Back to top

dna-sequencing: Archive

Zacks Equity Research

REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research

Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.

REGNPositive Net Change BAYRYPositive Net Change HALOPositive Net Change ALLOPositive Net Change

Urmimala Biswas

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.

DGXNegative Net Change NVDANegative Net Change BTAIPositive Net Change PLTRNegative Net Change TEMNegative Net Change

Kevin Cook

NVIDIA GTC: 7 Big Takeaways from Jensen

The Wizard of AI never fails to wow the crowd and Tuesday's keynote was no exception

NVDANegative Net Change